```
=> d his

     (FILE 'HOME' ENTERED AT 12:20:49 ON 20 FEB 2008)

     FILE 'MEDLINE, AGRICOLA, WPIX, BIOSIS, ESBIOBASE, CONFSCI, CAPLUS,
     DISSABS, EMBASE, SCISEARCH' ENTERED AT 12:21:05 ON 20 FEB 2008
L1          894 S (FADS2 OR DELTA6-DESATURASE OR LINOLEOYL-COA DESATURASE)
L2            2 S L1 AND PRESENILIN
L3            1 DUP REM L2 (1 DUPLICATE REMOVED)
L4            2 S L1 AND NICASTRIN
L5            1 DUP REM L2 (1 DUPLICATE REMOVED)
L6            6 S L1 AND APP
L7            4 DUP REM L6 (2 DUPLICATES REMOVED)
L8            0 S L1 AND NOTCH
L9            2 S L1 AND BACE
L10           2 DUP REM L9 (0 DUPLICATES REMOVED)
L11           6 S L1 AND ALZHEIMER
L12           5 DUP REM L11 (1 DUPLICATE REMOVED)

=> s l11 and (gamma-secretase)
L13           2 L11 AND (GAMMA-SECRETASE)

=> dup rem l13
PROCESSING COMPLETED FOR L13
L14           1 DUP REM L13 (1 DUPLICATE REMOVED)

=> d l14 ibib abs

L14  ANSWER 1 OF 1  WPIX COPYRIGHT 2008       THE THOMSON CORP on STN DUPLICATE
     1
ACCESSION NUMBER:     2005-223334 [23]   WPIX
CROSS REFERENCE:      2005-242127; 2005-591561; 2005-591643; 2005-597796;
                      2005-684094; 2006-164656; 2006-164657; 2006-414402
DOC. NO. CPI:         C2005-071587 [23]
TITLE:                Use of a FADS2 interacting molecule for
                      preparing a pharmaceutical composition for treating
                      neurodegenerative diseases
DERWENT CLASS:        B04; D16
INVENTOR:             HOPF C; DREWES G; RUFFNER H
PATENT ASSIGNEE:      (CELL-N) CELLZOME AG
COUNTRY COUNT:        107

PATENT INFO ABBR.:

      PATENT NO      KIND DATE     WEEK     LA  PG          MAIN IPC
      ------------------------------------------------------------------
      WO 2005023833   A2 20050317 (200523)* EN  488[7]
      EP 1670903      A2 20060621 (200643)  EN
      US 20060216292  A1 20060928 (200664)  EN
      US 20070161554  A1 20070712 (200747)# EN
      CN 1925869      A  20070307 (200752)  ZH
      IN 2006CN02799  P4 20070608 (200752)  EN
      EP 1670903      B1 20070829 (200757)  EN
      DE 602004008658 E  20071011 (200782)  DE

APPLICATION DETAILS:

      PATENT NO      KIND                  APPLICATION    DATE
      ------------------------------------------------------------------
      WO 2005023833 A2                     WO 2004-EP9771 20040902
```

EP 1670903 A2	EP 2004-764730 20040902
EP 1670903 B1	EP 2004-764730 20040902
EP 1670903 A2	WO 2004-EP9771 20040902
US 20060216292 A1	WO 2004-EP9771 20040902
EP 1670903 B1	WO 2004-EP9771 20040902
US 20070161554 A1	WO 2004-EP13457 20041126
CN 1925869 A	CN 2004-80042303 20041129
IN 2006CN02799 P4	WO 2004-EP13538 20041129
US 20060216292 A1	US 2006-570909 20060329
IN 2006CN02799 P4	IN 2006-CN2799 20060728
US 20070161554 A1	US 2007-594213 20070119
DE 602004008658 E	DE 2004-602004008658 20040902
DE 602004008658 E	EP 2004-764730 20040902
DE 602004008658 E	WO 2004-EP9771 20040902

FILING DETAILS:

PATENT NO	KIND		PATENT NO	
EP 1670903	A2	Based on	WO 2005023833	A
EP 1670903	B1	Based on	WO 2005023833	A
DE 602004008658 E		Based on	EP 1670903	A
DE 602004008658 E		Based on	WO 2005023833	A

PRIORITY APPLN. INFO:

EP 2004-18874	20040809
EP 2003-19642	20030905
WO 2003-EP13980	20031210
EP 2004-1894	20040129
EP 2004-1895	20040129
EP 2004-7447	20040326
WO 2004-EP4891	20040507
WO 2004-EP4889	20040507
DE 2004-102004007447	20040326
US 2007-594213	20070119

AN 2005-223334 [23] WPIX

CR 2005-242127; 2005-591561; 2005-591643; 2005-597796; 2005-684094; 2006-164656; 2006-164657; 2006-414402

AB WO 2005023833 A2 UPAB: 20060122

NOVELTY - A FADS2 interacting molecule useful for preparing a pharmaceutical composition for treating neurodegenerative diseases, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) identifying a gamma secretase and/or beta secretase inhibitor;

(2) preparing a pharmaceutical composition for treating neurodegenerative diseases;

(3) a protein complex comprising FADS2 and one or more proteins of the Nicastrin, BACE1, PTK7 or Psen2 complex;

(4) preparing and optionally analyzing the complex or its components;

(5) a nucleic acid construct containing one or more nucleic acids encoding the proteins of the complex;

(6) a host cell containing the nucleic acid construct;

(7) a kit comprising in one container the complex, optionally together with an antibody against the complex and/or further components such as reagents and working instructions;

(8) an array in which at least the complex is attached to a solid carrier;

(9) a process for processing a substrate of the complex;

(10) a pharmaceutical composition comprising the protein complex;

(11) screening for a molecule that binds to the complex;
(12) screening for a molecule that modulates directly or indirectly the function, activity, composition or formation of the complex;
(13) producing the pharmaceutical composition;
(14) diagnosing or screening for the presence of a disorder or predisposition for developing a disorder characterized by aberrant amount, component disposition or intracellular localization of the complex; and
(15) treating or preventing a disorder characterized by aberrant amount, component disposition or intracellular localization of the complex.
ACTIVITY - Neuroprotective.
No biological data given.
MECHANISM OF ACTION - Gene therapy.
USE - The FADS2 interacting molecule is useful for modulating gamma secretase and/or beta secretase activity in vitro. The FADS2 interacting molecule is useful for modulating the amount, activity or protein components of the complex for preparing a pharmaceutical composition for diagnosing, treating or preventing neurodegenerative diseases, e.g., Alzheimer's disease. The complex is useful as a target for an active agent of a pharmaceutical composition for treating or preventing neurodegenerative diseases e.g., Alzheimer's disease. (All claimed.)

=> d his

(FILE 'HOME' ENTERED AT 12:20:49 ON 20 FEB 2008)

FILE 'MEDLINE, AGRICOLA, WPIX, BIOSIS, ESBIOBASE, CONFSCI, CAPLUS, DISSABS, EMBASE, SCISEARCH' ENTERED AT 12:21:05 ON 20 FEB 2008

```
L1          894 S (FADS2 OR DELTA6-DESATURASE OR LINOLEOYL-COA DESATURASE)
L2            2 S L1 AND PRESENILIN
L3            1 DUP REM L2 (1 DUPLICATE REMOVED)
L4            2 S L1 AND NICASTRIN
L5            1 DUP REM L2 (1 DUPLICATE REMOVED)
L6            6 S L1 AND APP
L7            4 DUP REM L6 (2 DUPLICATES REMOVED)
L8            0 S L1 AND NOTCH
L9            2 S L1 AND BACE
L10           2 DUP REM L9 (0 DUPLICATES REMOVED)
L11           6 S L1 AND ALZHEIMER
L12           5 DUP REM L11 (1 DUPLICATE REMOVED)
L13           2 S L11 AND (GAMMA-SECRETASE)
L14           1 DUP REM L13 (1 DUPLICATE REMOVED)
```

=>